Status:

COMPLETED

Clinical Performance Evaluation of SARS-CoV-2 (COVID-19) Antigen Assay in Point of Care Settings

Lead Sponsor:

Freedom For All Diagnostics

Collaborating Sponsors:

CSSi Life Sciences

Conditions:

Covid-19

Eligibility:

All Genders

2-94 years

Brief Summary

The purpose of this study is to evaluate the performance of Freedom For All Diagnostics, Inc.'s colloidal gold immune technology SARS-CoV-2 Antigen investigational assay when compared to a high-sensit...

Detailed Description

The objective of this study is to demonstrate that non-laboratory personnel can accurately perform the SARS-CoV-2 Antigen assay in the intended use environment using nasopharyngeal samples by demonstr...

Eligibility Criteria

Inclusion

  • Subject suspected of having COVID-19 infection and within 7 days of symptom onset. This will include at least one of the following:
  • Fever or chills
  • Cough
  • Shortness of breath or difficulty breathing
  • Fatigue
  • Muscle or body aches
  • Headache
  • New loss of taste or smell
  • Sore throat
  • Congestion or runny nose
  • In addition to the above primary symptoms, the Subject might also report nausea, vomiting and/or diarrhea, but these symptoms alone are not sufficient to include the Subject in the study.
  • Subject is willing to provide consent/assent.
  • Subject is willing to have two (2) nasopharyngeal swabs collected for the study and in the event of inconclusive results, be willing to return to the site to have two (2) more nasopharyngeal swabs

Exclusion

  • To be enrolled in the study, each Subject must not meet:
  • Subject unable or unwilling to provide informed consent/assent.
  • Subject tested positive for SARS-CoV-2 within the past 3 months.
  • Subject has already participated in this study.
  • Subject is a vulnerable population and deemed inappropriate for study by site Principal Investigator and/or IRB.

Key Trial Info

Start Date :

January 27 2022

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 1 2022

Estimated Enrollment :

232 Patients enrolled

Trial Details

Trial ID

NCT05213897

Start Date

January 27 2022

End Date

June 1 2022

Last Update

June 2 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centennial Medical

Elkridge, Maryland, United States, 21075